This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2014 Jul;11(7):379.

doi: 10.1038/nrclinonc.2014.99. Epub 2014 Jun 10.

Targeted therapies: TH3RESA trial, overcoming hurdles in breast cancer

M Teresa Villanueva

PMID: 24913372
DOI: 10.1038/nrclinonc.2014.99

Comment

Targeted therapies: TH3RESA trial, overcoming hurdles in breast cancer

M Teresa Villanueva. Nat Rev Clin Oncol. 2014 Jul.

. 2014 Jul;11(7):379.

doi: 10.1038/nrclinonc.2014.99. Epub 2014 Jun 10.

Author

M Teresa Villanueva

PMID: 24913372
DOI: 10.1038/nrclinonc.2014.99

No abstract available

PubMed Disclaimer

Comment on

Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial.
Krop IE, Kim SB, González-Martín A, LoRusso PM, Ferrero JM, Smitt M, Yu R, Leung AC, Wildiers H; TH3RESA study collaborators. Krop IE, et al. Lancet Oncol. 2014 Jun;15(7):689-99. doi: 10.1016/S1470-2045(14)70178-0. Epub 2014 May 2. Lancet Oncol. 2014. PMID: 24793816 Clinical Trial.

References

1. Lancet Oncol. 2014 Jun;15(7):689-99 - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
- Ovid Technologies, Inc.
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information